# Peptomyc SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peptomyc-sl

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.peptomyc.com
- Total disclosed funding: $6.2M
- Latest round: Series A (Sep 6, 2017)
- Investors on record: 2

## About

Peptomyc SL is a biotechnology company based in Spain, specializing in the development of innovative cancer therapies, particularly through its first-in-class MYC inhibitor, OMO-103. Founded in 2014, Peptomyc SL operates from its headquarters in Barcelona, Spain, focusing on the design and development of cancer treatments. The company was established by Laura Soucek, who has a history of involvement in biotechnology ventures. In September 2026, Peptomyc SL raised EUR 5.7 million in venture funding from Institut Català de Finances. Peptomyc is at the forefront of cancer treatment innovation with its flagship product, OMO-103, a first-in-class MYC inhibitor. This mini-protein therapeutic directly targets MYC, a critical transcription factor that regulates tumor proliferation and survival, thereby addressing the high unmet medical needs of patients with cancers characterized by abnormal MYC activity. OMO-103 utilizes patented cell-penetrating properties to enable effective delivery to the nuclei of cancer cells, thereby facilitating targeted eradication while minimizing impact on healthy tissues. The product is currently being developed and tested in multiple clinical trials, including a Phase 2 trial for advanced osteosarcoma and a Phase Ib trial for pancreatic ductal adenocarcinoma (PDAC). Peptomyc primarily serves the oncology market, and its advancements in MYC inhibition are poised to benefit a broad range of cancer patients globally, particularly in regions such as North America and Europe. Peptomyc’s revenue model centers around the development and commercialization of its proprietary therapeutic products, specifically OMO-103. The transactions typically occur through partnerships with pharmaceutical companies and research institutions focused on oncology. As the company progresses through clinical trials, it aims to establish agreements for licensing and distribution of its products, enhancing its market presence. The financial structure may involve milestone payments, royalties on sales, and potential collaborations for co-development with strategic partners. Specific pricing plans and financial arrangements are tailored to the unique nature of the oncology therapeutics market, reflecting the crucial role of OMO-103 in addressing complex therapeutic challenges. In 2023, Peptomyc reported a revenue of EUR 0 and an EBITDA of EUR -190,151.9. The company will use the September 2026 funding to support ongoing OMO-103 clinical trials, advance manufacturing readiness for later-stage development, and pursue pharmaceutical partnership discussions.

## Funding rounds

- Series A, Sep 6, 2017, $5.1M — Riva y Garcia Private Equity, Alta Life Sciences
- Seed, Apr 27, 2016, $1.1M — Riva y Garcia Private Equity

## Investors

- Riva y Garcia Private Equity (https://capitalatlas.ai/funds/riva-y-garcia-private-equity) — Seed, Series A
- Alta Life Sciences — Series A